AI
RPRX icon

Atria Investments’s Royalty Pharma RPRX Stock Holding History

Atria Investments’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Sell
6,589
-8,752
-57% -$456K ﹤0.01% 1707
2026
Q1 		$736K Buy
15,341
+1,212
+9% +$53.1K 0.01% 1235
2025
Q4 		$546K Buy
14,129
+2,362
+20% +$90.1K 0.01% 1388
2025
Q3 		$415K Buy
11,767
+3,530
+43% +$128K ﹤0.01% 1526
2025
Q2 		$297K Sell
8,237
-1,065
-11% -$35.3K ﹤0.01% 1720
2025
Q1 		$290K Sell
9,302
-13,331
-59% -$423K ﹤0.01% 1636
2024
Q4 		$577K Sell
22,633
-20,550
-48% -$545K 0.01% 1252
2024
Q3 		$1.22M Sell
43,183
-7,639
-15% -$212K 0.02% 876
2024
Q2 		$1.34M Buy
50,822
+11,803
+30% +$327K 0.02% 801
2024
Q1 		$1.19M Buy
+39,019
New +$1.15M 0.02% 881

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Atria Investments's RPRX Position: Q2 2026 in Review

Atria Investments reduced its Royalty Pharma (RPRX) stake by 57% in Q2 2026, selling an estimated $456K and leaving 6,589 shares worth $369K. The position accounts for ﹤0.01% of the portfolio, ranked #1707.

Atria Investments first reported a position in RPRX in Q1 2024 and has held it in 10 quarters since. The position peaked at $1.34M in Q2 2024. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Atria Investments held 6,589 shares of Royalty Pharma worth $369K as of Q2 2026.
  • Atria Investments sold 8,752 Royalty Pharma shares in Q2 2026, an estimated $456K.
  • Royalty Pharma made up ﹤0.01% of Atria Investments's portfolio in Q2 2026, its #1707 holding.
  • Atria Investments first reported a position in Royalty Pharma in Q1 2024 and has held it in 10 quarters since.
  • Atria Investments's Royalty Pharma position peaked at $1.34M in Q2 2024.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.